Attenuated live virus vaccinations are generally recommended 24 months following hematopoietic cell transplantation (HCT) in patients not receiving immunosuppressive therapy. To date, there are no data regarding the safety of live-attenuated herpes zoster or measles-mumps-rubella (MMR) vaccinations in multiple myeloma patients on maintenance lenalidomide or bortezomib following autologous HCT. One hundred thirty-seven multiple myeloma patients on maintenance lenalidomide or bortezomib post-auto-HCT who received either MMR or herpes zoster vaccine were analyzed and any adverse events documented in the medical record in the 42 days following vaccination were recorded. Patients were vaccinated a median of 25 months (range, 18-62) post transplant. The most common post-vaccination adverse event was upper respiratory tract infection (18/137 patients); no rash attributed to vaccine strains or other adverse outcomes potentially related to the vaccines were identified. MMR and herpes zoster vaccination were safe and well-tolerated in this cohort.
Waning immunity against vaccine-preventable diseases and impaired host defenses following autologous hematopoietic cell transplantation (auto-HCT) predispose recipients to increased risk and severity of infectious complications. Most HCT recipients become seronegative to measles after transplantation [1] with reports of severe and fatal measles after HCT [2] . Measles-mumps-rubella (MMR) revaccination may help restore immunity and is recommended 24 months after auto-HCT [3, 4] . Varicella zoster virus (VZV) reactivation occurs in 30-53% of patients in the first 5 years post HCT [5, 6] , depending on the type of HCT (autologous versus allogeneic) with the highest risk occurring during the first year after transplantation. Even when antiviral prophylaxis is used, its effectiveness is dependent upon ongoing prophylactic treatment; once such measures are discontinued, the incidence of VZV reactivation is again increased [7, 8] . VZV vaccination is also recommended 24 months post-auto-HCT provided patients are not receiving immunosuppressive medications [9] . However, insufficient data or accurate information regarding the safety, immunogenicity, and efficacy of vaccination in HCT recipients contributes to low vaccination rates after transplantation.
Multiple myeloma patients who receive lenalidomide or bortezomib maintenance after auto-HCT present additional challenges. There are no data regarding the safety of live virus vaccinations in patients receiving these drugs. Lenalidomide is an analog of thalidomide with immunomodulatory, antiangiogenic, and antineoplastic properties [10] . Bortezomib is a proteasome inhibitor that exerts its antineoplastic activity through induction of apoptosis [11] . Both lenalidomide and bortezomib are being increasingly used for maintenance therapy after auto-HCT in multiple myeloma patients [12] . Due to lack of data, live virus vaccination is generally avoided in this group because of safety concerns.
Autologous and allogeneic HCT recipients at our institution receive live virus vaccination including MMR and herpes zoster vaccine about 24 months after transplantation if they are free of graft-versus-host disease (allogeneic), not receiving immunosuppressive therapy and are not taking prophylactic antivirals (acyclovir, valacyclovir, or famciclovir). The recommendation to use the zoster vaccine (Zostavax) instead of the varicella vaccine (Varivax) was made by a multidisciplinary team given the high risk of VZV reactivation in this population after prophylaxis discontinuation and the increased morbidity from VZV in this population including the development of post-herpetic neuralgia [13] .
We report on the safety and tolerability of live virus vaccination with MMR and VZV vaccines in multiple myeloma patients receiving bortezomib or lenalidomide after auto-HCT at our center. We reviewed the medical records of multiple myeloma patients who underwent auto-HCT at Dana-Farber Cancer Institute between May 2007 and January 2014 who met the following criteria: on maintenance lenalidomide or bortezomib after auto-HCT, and received either MMR or herpes zoster vaccine. Patients were excluded from the herpes zoster cohort if they were taking acyclovir, valacyclovir, or famciclovir for herpes virus prophylaxis, or if they restarted these antivirals for prophylaxis within 42 days after vaccination. The 42-day period for monitoring of adverse events was selected for consistency with other safety studies of live virus vaccination including previous studies of the live virus herpes zoster vaccine. The study was approved by the office for human research studies (OHRS) at Dana-Farber/Harvard Cancer Center.
Given lack of data on safety of live virus MMR and herpes zoster vaccination in this population, the decision whether to vaccinate or not was left to the discretion of the treating oncologist. Patients received the MMR vaccine (Merck & Co, INC, Whitehouse Station, NJ, USA), 0.5 mL dose containing at least 1000 TCID50 (tissue culture infectious doses) of measles virus; 12,500 TCID50 of mumps virus; and 1000 TCID50 of rubella virus. The herpes zoster vaccine used was Zostavax (Merck & Co, INC, Whitehouse Station, NJ, USA) administered as 0.65 mL subcutaneous injection and containing at least 19,400 plaque-forming units of the Oka/Merck strain of attenuated live varicella zoster virus.
Patient characteristics, absolute lymphocyte count at the time of vaccination, and all adverse events including skin rashes, infectious complications, hospitalizations, and urgent care visits were recorded until day 42 after vaccination. New prescriptions for acyclovir, valacyclovir, or famciclovir within 42 days post vaccination were also captured as indicators of suspected vaccine-related herpes zoster infection.
One hundred thirty-seven patients met inclusion criteria. One hundred thirty-six received the MMR vaccine and 70 patients received the live-attenuated herpes zoster vaccine. Sixty-nine patients received both. The characteristics of the MMR and herpes zoster vaccine cohorts are shown in Table 1 .
The adverse events within 42 days after vaccinations are shown in Table 2 . The median time to onset of adverse events was 28 days (range, 3-49 days). The most common adverse event was upper respiratory tract infection (URI), which was noted in 18/136 patients (13.2%) in the MMR cohort and 10/70 patients (14.3%) in the herpes zoster vaccine cohort. Six patients in the MMR cohort and two patients in the herpes zoster vaccine cohort were prescribed antimicrobials for treatment for their URI, while the rest were managed symptomatically. Skin rash was reported in six patients (4.4%) in the MMR cohort. Of those six patients, two patients had a vesicular rash and were diagnosed with herpes zoster after acyclovir prophylaxis was discontinued, thus requiring anti-VZV therapy. Neither of these patients received the herpes zoster vaccine concomitantly with MMR. Two patients had urticarial rash that resolved without specific therapy, and two patients had nonspecific skin rash (groin rash, a patch of dry skin). None of the patients in the MMR cohort developed a morbilliform rash suggestive of measles or rubella.
Of the 70 patients who received the herpes zoster vaccine, 58 were VZV seropositive prior to auto-HCT. All patients had discontinued herpes zoster antiviral prophylaxis prior to vaccination. No patient developed a vesicular rash, was diagnosed with herpes zoster, or required treatment with acyclovir, valacyclovir, or famciclovir for suspected herpes zoster. Two patients (2.9%) developed a non-specific rash that required no therapy and spontaneously resolved. Of note, one patient with previous history of herpes zoster and post-herpetic neuralgia (PHN) reported worsening of PHN without appearance of new skin rash after vaccine administration. Two patients (1.5%) in the MMR cohort and one patient (1.4%) in the herpes zoster vaccine cohort reported having a transient fever following vaccination. None required an emergency room visit, hospitalization, or specific therapy. No hospitalizations or deaths were reported in either cohort in the 42 days following vaccination.
Most HCT recipients lose previously acquired protective immunity against vaccine-preventable diseases after transplantation and have delays in the production of naive T lymphocytes, which result in defects in the production of new antigen-specific T lymphocytes and an inability to produce antibodies [14] . Thus, vaccination soon after immune reconstitution is an important strategy to help restore immunity.
Lenalidomide is mainly an immunomodulatory, not an immunosuppressive, agent that inhibits myeloid cellmediated inflammatory immune function, increasing lymphoid immune function, augmenting NK T cell numbers and function and enhancing T cell cytokine production and proliferation [10] . This immunomodulatory activity of lenalidomide may enhance response to vaccination as demonstrated in a study of conjugated 7-valent pneumococcal vaccine in relapsed multiple myeloma patients who were receiving lenalidomide [10] . On the other hand, bortezomib may have an immunosuppressive effect since it has been associated with hepatitis B, HSV, and VZV reactivation [15] .
We now provide data regarding safety of live virus vaccination in this population. The decision to give live virus vaccination was made by the primary oncologist based on overall clinical performance and whether a patient was on immunosuppressive treatments. None of the patients developed any illness attributed to the vaccine strains within 42 days of vaccination. The vaccines were generally welltolerated with few adverse events. No patient died or required hospitalization within the 42 days follow-up period. URI symptoms observed following vaccination may or may not be related to vaccination and were usually selflimited. There were no skin rashes attributed to any of the vaccine strains. One interesting observation noted is that one patient with pre-existing PHN who received the herpes zoster vaccine had worsening of her pain without development of a rash. It is unclear at this point what is the underlying mechanism that led to worsening of pain in this situation.
This study has several limitations. It is a retrospective study and therefore lacks the increased precision of a prospective study. The cohort was relatively small, especially regarding patients on bortezomib. The vaccination was given at the treating physician's discretion which may have introduced a selection bias. Only clinically relevant adverse events were documented in the chart. Less severe or transient side effects may have been missed from this analysis if not documented. The study did not examine the immunogenicity and efficacy of these vaccines in this population.
In summary, MMR and herpes zoster vaccination administered around 24 months after auto-HCT appears to be safe and well-tolerated in multiple myeloma patients on maintenance lenalidomide. The safety of vaccination in patients receiving maintenance bortezomib needs further observation given the small number of patients in this group. (1) b Patient with pre-existing post-herpetic neuralgia reported increased pain after vaccine administration but did not develop a skin rash
